Rocuronium Pharmacokinetics and Dosing in Organ Dysfunction

Elimination Pathways

• Rocuronium is eliminated primarily unchanged via the kidneys (urinary excretion) and the biliary system (biliary/fecal excretion), with minimal reliance on hepatic enzymatic metabolism. 1, 2

Dose‑Adjustment Recommendations

Renal Insufficiency

• The initial rocuronium dose does not require modification in patients with any degree of renal impairment. 3, 1, 2
• The onset of neuromuscular blockade (time to clinical effect) remains unchanged in renal failure. 1, 2

Hepatic Insufficiency (Cirrhosis)

• The initial rocuronium dose for tracheal intubation (≥0.6 mg kg⁻¹) should not be altered in cirrhotic patients; any pharmacokinetic changes are clinically insignificant at this dose. 3, 1, 2
• Although the volume of distribution is increased in liver disease, resulting in lower plasma concentrations, this does not affect the efficacy of the standard intubating dose. 1, 2

Variability with Repeated Dosing

• In cirrhotic patients, repeated rocuronium administrations produce a wide inter‑individual variability in the duration of action. 1, 2
• Populations with renal or hepatic insufficiency exhibit greater inter‑individual variability overall, complicating dose titration. 1, 4

Alternative Neuromuscular Blocking Agents in Organ Dysfunction

• For patients with renal and/or hepatic impairment, a benzylisoquinolinium muscle relaxant (e.g., atracurium or cisatracurium) is recommended as the preferred alternative because its elimination is organ‑independent (Hofmann degradation and ester hydrolysis). This recommendation carries a GRADE 2+ level of evidence. 1, 5, 4

All facts are derived from peer‑reviewed sources and are presented with their corresponding citation identifiers.